Business Description
NurExone Biologic Inc
NAICS : 325410
SIC : 3741
ISIN : CA67059R1091
Total Employee Number:
16Description
NurExone Biologic Inc is a company that focuses on developing biological and minimally invasive treatments for Spinal Cord Injury and Traumatic Brain Injury. Its primary product is ExoTherapy, which is an exosome therapy production platform. It is developing ExoPTEN, a product that utilizes ExoTherapy for the treatment of acute Spinal Cord Injuries (SCI). It also aims to monetize its proprietary ExoTherapy technology and production platform by licensing it to the biopharmaceutical industry for other diseases and indications.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 22.28 | |||||
Equity-to-Asset | 0.64 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | -0.01 | |||||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 28.7 | |||||
3-Year EPS without NRI Growth Rate | 18.3 | |||||
3-Year FCF Growth Rate | 17.4 | |||||
3-Year Book Growth Rate | -14 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 92.88 | |||||
9-Day RSI | 84.73 | |||||
14-Day RSI | 76.16 | |||||
3-1 Month Momentum % | -21.39 | |||||
6-1 Month Momentum % | -20.34 | |||||
12-1 Month Momentum % | -31.18 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.23 | |||||
Quick Ratio | 2.23 | |||||
Cash Ratio | 1.98 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -28.4 | |||||
Shareholder Yield % | -9.24 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -354.43 | |||||
ROA % | -215.98 | |||||
ROIC % | -479.24 | |||||
3-Year ROIIC % | -53.18 | |||||
ROC (Joel Greenblatt) % | -733.69 | |||||
ROCE % | -298.22 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 17.82 | |||||
Price-to-Tangible-Book | 17.82 | |||||
EV-to-EBIT | -3.45 | |||||
EV-to-EBITDA | -3.55 | |||||
EV-to-FCF | -4.63 | |||||
| Price-to-Net-Current-Asset-Value | 35.64 | |||||
| Price-to-Net-Cash | 35.64 | |||||
Earnings Yield (Greenblatt) % | -28.99 | |||||
FCF Yield % | -20.28 |
GF Valueâ„¢
NurExone Biologic Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
NurExone Biologic Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Guru Commentaries on OTCPK:NRXBF
No articles.
Press Release
| Subject | Date | ||
|---|---|---|---|
| The Watchlist by The Market Herald Releases New Interviews with NurExone Biologic and SuperBuzz Discussing Their Latest News | 2023-09-13 |
Articles on NurExone Biologic Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers